{"url_path":"/sec/ngne/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000050-index.html","accession_number":"0001404644-26-000050","cik":"0001404644","ticker":"NGNE","issuer_name":"Neurogene Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000050-index.html","primary_entity_key":"0001404644","primary_entity_name":"Neurogene Inc."},"word_count":108,"has_tables":true,"body_markdown":"Item 9.01Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n  Description\n\n1.1\n[Underwriting Agreement, dated as of June 30, 2026, by and among Neurogene Inc. and Leerink Partners LLC, Stifel, Nicolaus & Company](ngne-june2026cmpoxunderwri.htm)[,](ngne-june2026cmpoxunderwri.htm)[Inc](ngne-june2026cmpoxunderwri.htm)[orporated](ngne-june2026cmpoxunderwri.htm)[and Guggenheim Securities, LLC](ngne-june2026cmpoxunderwri.htm)\n\n4.1\n[Form of Pre-Funded Warrant](ngne-june2026cmpoxformofpr.htm)\n\n5.1\n[Opinion of Gibson, Dunn & Crutcher LLP](ngne-june2026cmpox51opinio.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nNEUROGENE INC.\n\nDate: July 1, 2026By:/s/ Christine Mikail\n\nName: Christine Mikail\n\nTitle: President, Chief Financial Officer"}